Medixon 500

Myanmar • Dexa Medica

Indication

  • Endocrine disorders
  • Allergic disorders
  • Dermatologic disorders
  • Gastrointestinal disorders
  • Hematologic disorders
  • Hepatic diseases
  • Nonrheumatoid inflammation
  • Neoplastic diseases
  • Nephrotic syndrome
  • Neurologic diseases
  • Neurotrauma
  • Ophthalmic disorders
  • Pericarditis
  • Nasal polyps
  • Respiratory disorders

Composition

Methylprednisolone 500 mg

Package

1 vial of 500 mg and 1 ampoule of 8 ml

Dosage Forms

Powder for Injection

ATC Classification

H02A

Warning

Alcohol
Consult Your Doctor
Safety of this item for use with alcohol has not been established. Please consult your doctor.
Machinery
Not Recommended
This item should not be used while operating heavy machinery.
Pregnancy
Caution
This item may not be safe for use during pregnancy. Use with caution and after consultation with your doctor.
Lactation
Caution
This item may not be safe for use during lactation. Use with caution and after consultation with your doctor.

Pregnancy & Nursing Mother
Medixon may cause fetal damage when administered to pregnant women and can diffuse into breast milk and may suprpess growth or cause other side effects in nursing infants.

Children
Medixon should be avoided cause might be retared the bone growth. If therapy is necessary, growth of infants must be closed monitored.

Geriatric Patient
Hypertension may occur during adrenocorticoid therapy, postmenopausal women may also be more likely be develop Glucocorticoid induced osteoporosis.

Long-term treatment may decrease body’s stamina to infection disease.

Dosage

Up to 18 Years Old

Adrenocortical insufficiency:
Intramuscular, 0.18 mg (base) per kg of body weight or 3.33 mg (base) per square meter of body surface area daily (in three divided doses) every third day.

Acute spinal cord injury treatment:
intravenous, 30 mg (base) per kg of body weight administered over a 15 minutes, followed after 45 minutes by a continuous infusion of 5.4 mg per kg of body weight per hour, for 23 hours.

Adjunctive treatment in patients with Pneumocystis Carinii Pneumonia associated with AIDS:

  • Children up to 14 years of age: dosage has not been established.
  • Children 14 years of age or older: see Adults and adolescent dose.

Other indications:
Intramuscular, 0.14-0.84 mg (base) per kg of body weight or 4.16-25 mg (base) per square meter of body surface every 12 to 24 hours.

18 Years Old and Above

IM or IV, 10-40 mg (base), repeated as needed.

High dose (pulse therapy):
IV, 30 mg (base) per kg of body weight administered over at least 30 minutes. This dose may be repeated every 4-6 hours for 48 hours.

Acute exacerbations of multiple sclerosis:
intramuscular or intravenous, 160 mg (base) daily for 1 week, followed by 64 mg (base) every other day for 1 month.

Acute spinal cord injury treatment:
intravenous, 30 mg (base) per kg of body weight administered over 15 minutes, followed after 45 minutes by a continuous infusion of 5.4mg per kg of body weight per hour, for 23 hours.

Adjunctive treatment in patients with Pneumocystis carinii pneumonia associated with AIDS:
Intravenous, 30 mg (base) twice daily on days one through five, 30 mg once daily on days six through ten, and 15 mg once daily on days eleven through twenty-one.

Direction for Use

IM or IV injection:
Reconstitute powder by adding solvent (containing benzyl alcohol 0.9%), mix homogeneously. Direct intravenously can be given at least 1 minute or can be given by intravenously infusion in dextrose 5%, NaCl 0.9% or dextrose 5% in NaCl 0.9% for at least 30 minutes. The solution is stable physically and chemically for 48 hours.

Reconstitute powder by adding 8 ml solvent, mix homogeneously.

See All Products